The Leading Community for Trusted Peptide Research & Insights
Research summaries, dosing protocols, and community reports for peptides. Built on clinical data and real-world experiences.
Weight loss peptides — particularly GLP-1 receptor agonists like Semaglutide and Tirzepatide — have become the most commercially significant peptide class in recent years. These compounds work by mimicking incretin hormones that regulate appetite, blood sugar, and metabolic rate.
The metabolic peptides listed below range from FDA-approved medications to experimental research compounds. We present the evidence objectively: what the clinical trials actually show, what the dosing protocols look like, and what side effects have been documented.
Based on clinical trial data, Tirzepatide (a dual GIP/GLP-1 agonist) has shown the largest average weight loss in Phase 3 trials — up to 22.5% body weight reduction at the highest dose. Semaglutide 2.4mg (Wegovy) showed approximately 15% average weight loss. Retatrutide (a triple agonist) showed up to 24% in Phase 2 trials.
Semaglutide (as Wegovy/Ozempic) and Tirzepatide (as Mounjaro/Zepbound) are FDA-approved for weight management or type 2 diabetes. Other metabolic peptides like AOD-9604, Retatrutide, and 5-Amino-1MQ are not FDA-approved and remain in research stages.
GLP-1 receptor agonists reduce appetite by acting on brain regions that control hunger and satiety, slow gastric emptying (making you feel full longer), and improve insulin sensitivity. Dual and triple agonists like Tirzepatide and Retatrutide add GIP and/or glucagon receptor activation for additional metabolic effects.